264 related articles for article (PubMed ID: 24855206)
1. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy.
Stemberger C; Graef P; Odendahl M; Albrecht J; Dössinger G; Anderl F; Buchholz VR; Gasteiger G; Schiemann M; Grigoleit GU; Schuster FR; Borkhardt A; Versluys B; Tonn T; Seifried E; Einsele H; Germeroth L; Busch DH; Neuenhahn M
Blood; 2014 Jul; 124(4):628-37. PubMed ID: 24855206
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
Front Immunol; 2021; 12():694588. PubMed ID: 34489940
[TBL] [Abstract][Full Text] [Related]
4. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
5. Big bang theory of stem-like T cells confirmed.
Restifo NP
Blood; 2014 Jul; 124(4):476-7. PubMed ID: 25061170
[TBL] [Abstract][Full Text] [Related]
6. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation.
Poiret T; Axelsson-Robertson R; Remberger M; Luo XH; Rao M; Nagchowdhury A; Von Landenberg A; Ernberg I; Ringden O; Maeurer M
Front Immunol; 2018; 9():760. PubMed ID: 29692783
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
9. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
10. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation.
Liu J; Chang YJ; Yan CH; Xu LP; Jiang ZF; Zhang XH; Liu KY; Huang XJ
J Infect; 2016 Sep; 73(3):261-70. PubMed ID: 27311748
[TBL] [Abstract][Full Text] [Related]
11. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
12. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.
Thomas S; Klobuch S; Besold K; Plachter B; Dörrie J; Schaft N; Theobald M; Herr W
Eur J Immunol; 2012 Dec; 42(12):3442-53. PubMed ID: 22930221
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
14. Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice.
Wikstrom ME; Fleming P; Kuns RD; Schuster IS; Voigt V; Miller G; Clouston AD; Tey SK; Andoniou CE; Hill GR; Degli-Esposti MA
Blood; 2015 Sep; 126(12):1503-14. PubMed ID: 26130706
[TBL] [Abstract][Full Text] [Related]
15. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
[TBL] [Abstract][Full Text] [Related]
16. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
18. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
20. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]